Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05024_nanopub.RA8CVNjeOLfhSfThQMX3Il0QGFz3H1X9EiMtDuDtxY-dI#assertion>. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05024 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05024 label "CTA018 [drugbank:DB05024]" assertion.
- drugbank:DB05024 seeAlso DB05024 assertion.
- drugbank:DB05024 identifier "drugbank:DB05024" assertion.
- drugbank:DB05024 description "CTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vitamin D) and a potent activator of vitamin D signaling pathways. CTA018 will be the first drug with this novel dual mechanism of action to enter clinical development. Preclinical studies have shown that CTA018 inhibits the proliferation of rapidly dividing cells such as human epidermal keratinocytes (skin cells) and is also effective in inhibiting pro-inflammatory cytokine secretion which may be involved in the etiology of psoriasis. Cytochroma anticipates that CTA018 will be more potent than currently marketed vitamin D analogues such as calcitriol and calcipotriol and it is expected to have a greater safety index." assertion.
- drugbank:DB05024 title "CTA018" assertion.
- drugbank:DB05024 bio2rdf_vocabulary:identifier "DB05024" assertion.
- drugbank:DB05024 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05024 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05024" assertion.
- drugbank:DB05024 bio2rdf_vocabulary:x-identifiers.org DB05024 assertion.
- drugbank:DB05024 drugbank_vocabulary:drugbank-id "DB05024" assertion.
- drugbank:DB05024 drugbank_vocabulary:x-cas cas: assertion.